Mosti M P, Flemmen G, Hoff J, Stunes A K, Syversen U, Wang E
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Osteoporos Int. 2016 Mar;27(3):1003-1010. doi: 10.1007/s00198-015-3371-z. Epub 2015 Oct 26.
This study examined musculoskeletal health in amphetamine users, compared with healthy age-matched controls. We show that amphetamine users have reduced bone mass at several skeletal sites and attenuated maximal muscle strength and force development capacity in the lower extremities.
Amphetamine use may cause poor bone quality and elevated risk of osteoporosis. The purpose of this study was to investigate whether amphetamine users exhibit reduced regional and whole body bone mineral density (BMD), altered bone metabolism, and how muscle function may relate to the patient groups' skeletal health.
We assessed hip, lumbar spine and whole body BMD, and trabecular bone score (TBS) by dual x-ray absorptiometry (DXA), and bone metabolism markers in serum and maximal strength and force development capacity in 36 amphetamine users (25 men, 30 ± 7 years; 11 women 35 ± 10 years) and in 37 healthy controls (23 men, 31 ± 9 years; 14 women, 35 ± 7 years).
Whole body BMD was lower in amphetamine users (8% in males and 7% females, p < 0.01), as were BMD at the total hip and sub-regions of the hip (9-11% in men and 10-11 % in women, p < 0.05). Male users had 4% lower TBS (p < 0.05) and higher serum level of type 1 collagen amino-terminal propeptide (p < 0.01). This coincided with reduced lower extremity maximal strength of 30% (males, p < 0.001) and 25% (females, p < 0.05) and 27% slower muscular force development in males compared to controls (p < 0.01).
These findings demonstrate that amphetamine users suffer from a generalized reduction in bone mass, which was associated with attenuated maximal muscle strength and force development capacity in the lower extremities.
本研究对苯丙胺使用者的肌肉骨骼健康状况进行了检查，并与年龄匹配的健康对照组进行了比较。我们发现，苯丙胺使用者多个骨骼部位的骨量减少，下肢最大肌肉力量和力量发展能力减弱。
使用苯丙胺可能导致骨质不佳以及骨质疏松风险升高。本研究的目的是调查苯丙胺使用者是否存在局部和全身骨矿物质密度（BMD）降低、骨代谢改变，以及肌肉功能与患者组骨骼健康之间的关系。
我们通过双能X线吸收法（DXA）评估了36名苯丙胺使用者（25名男性，年龄30±7岁；11名女性，年龄35±10岁）和37名健康对照者（23名男性，年龄31±9岁；14名女性，年龄35±7岁）的髋部、腰椎和全身BMD、骨小梁骨评分（TBS），以及血清中的骨代谢标志物、最大力量和力量发展能力。
苯丙胺使用者的全身BMD较低（男性降低8%，女性降低7%，p<0.01），全髋部和髋部各亚区域的BMD也较低（男性降低9 - 11%，女性降低10 - 11%，p<0.05）。男性使用者的TBS降低4%（p<0.05），血清1型胶原氨基端前肽水平较高（p<0.01）。这与男性下肢最大力量降低30%（p<0.001）、女性降低25%（p<0.05）以及男性肌肉力量发展比对照组慢27%（p<0.01）相一致。
这些发现表明，苯丙胺使用者全身骨量普遍减少，这与下肢最大肌肉力量和力量发展能力减弱有关。
